ClinicalTrials.gg
Active, not recruitingNCT05737602Updated Jun 12, 2026

Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

An interventional study of 3RP-VHL in Von Hippel-Lindau Disease and Genetic Disorder, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in von Hippel-Lindau Disease with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. von Hippel-Lindau Disease · United States.

Planned enrollment
7th of 23
40 · median 15
Started
2024
the only one that year
No phase
2 of 33
1 open now
Registered
31st of 33
by date

Among the 33 studies in von Hippel-Lindau Disease with a site in United States, this one is the 7th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2024, is one of 2 with no phase, and was the 31st registered.

von Hippel-Lindau Disease

55 studies on the registry are indexed under von Hippel-Lindau Disease; 23 are open to participants now.

Browse von Hippel-Lindau Disease studies →

Open to participants now

8 of the 33 studies in von Hippel-Lindau Disease with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 von Hippel-Lindau Disease studies recruiting now, 16 (80%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in von Hippel-Lindau Disease with a site in United States, or all of them as a file.
02

Study summary

The Relaxation Response Resiliency Program (3RP) has shown efficacy in improving coping and resilience across diverse populations; however, little is known about how it helps individuals manage the challenges of living with a chronic illness. This study proposes to pilot test an adapted version of the 3RP among patients living with VHL.

Read the detailed description

The 3RP has not been carried out with VHL patients. As such, the investigators are looking to see if an adapted program, tailored to the needs of patients with VHL, is feasible, acceptable, and helpful in improving coping among individuals living with VHL.

This study is a two phase trial. Phase I is descriptive. It is comprised of conducting interviews with patients and caregivers to understand the challenges of living with VHL and patient's programatic needs. This information will be used to tailor the program for patients living with VHL. Phase II is a single-arm feasibility trial that will examine if the adapted program is feasible, acceptable, and helps promote stress management among VHL patients. To these means, we will test the adapted 3RP (3RP-VHL) in up to 40 patients living with VHL. Participants will complete surveys at baseline and post 3RP-VHL program completion. This record will reflect the trial component (Phase II) only, as feasibility and acceptability outcomes will be collected for this phase.

03

Conditions studied

  • Von Hippel-Lindau Disease
  • Genetic Disorder

Keywords

  • Von-Hippel-Lindau Disease
  • VHL
  • Genetic Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18+
  • Confirmed diagnosis of VHL

Exclusion criteria

Exclusion Criteria:

  • Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study PI).
  • Unwilling or unable to participate in study sessions delivered via Partners Telehealth videoconferencing.
  • Participated in Phase 1 qualitative interview.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    3RP-VHL

    * An adapted version of the 3RP (3RP-VHL) for individuals with VHL. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks. * Complete pre- and post-intervention surveys.

    Behavioral: 3RP-VHL

Interventions

  • Behavioral3RP-VHL

    An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals with VHL.

    Also known as: Relaxation Response Resiliency Program for VHL

06

What researchers measure

Primary outcomes

  1. 3RP-VHL Feasibility: Percent of Identified Eligibles Who Enroll

    Percent of identified eligibles who were approached (hence given the opportunity to participate) who enroll (i.e., sign consent and complete baseline).

    Time frame: Post-treatment completion (treatment is approximately 2 months)

  2. 3RP-VHL Feasibility: Proportion of Participants Completing the 3RP-VHL Program

    Among those who initiated the program, this is the proportion of patients who completed the program (defined as completing 6 out of 8 sessions). Participants who complete at least 75% of the treatment sessions (6 out of 8 sessions) will be identified as treatment completers.

    Time frame: Post-treatment completion (treatment is approximately 2 months)

  3. 3RP-VHL Acceptability: Five Questions

    Acceptability will be assessed with five questions rated on a 4-point Likert scale (1=not at all to 4=very). More specifically, acceptability will be defined as ≥75% of responses rated at least 3/4 on enjoyableness, convenience, helpfulness, future use, and satisfaction.

    Time frame: Post-treatment completion (treatment is approximately 2 months)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for May 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2023
First posted
Feb 21, 2023
StartActual
Jul 30, 2024
Primary completionEst.
May 1, 2027
CompletionEst.
Jul 1, 2028
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05737602
Collaborators
The Rappaport Foundation, The Claflin Distinguished Scholar Awards
Responsible party
Giselle K. Perez Lougee (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Feb 21, 2023
Start date
Jul 30, 2024
Primary completion
May 1, 2027 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Jun 12, 2026

Study contacts

Giselle Perez, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion